CDMO Growth Leverage BSP Pharmaceuticals as a full-spectrum CDMO capable of pre-clinical GLP through cGMP manufacturing for cytotoxic and high potent oncology drugs, immunotherapies, and complex biologics to broaden your outsourcing and late-stage development partnerships.

Specialized Capabilities Target opportunities in cytotoxic and high-potent drug products, antibody-drug conjugates, peptides, proteins, oligonucleotides, and nano medicines, where BSP’s containment facilities and scalable operations can support both development and commercial supply.

Global Partnerships Capitalize on BSP’s history of collaboration with U.S. and global biotech partners to pursue co-development or contract manufacturing deals, highlighting proven readiness to support cross-border programs and speed-to-market.

Mid-Sized Edge Position BSP as a high-capacity yet flexible CDMO option for mid-to-late-stage programs seeking robust compliance (GLP to cGMP) without engaging with mega-CGMP incumbents, offering competitive timelines and tailored development services.

Financial Opportunity With reported revenue in the wide seven-figure to low eight-figure range and a strong focus on oncology and innovative therapeutics, propose multi-year manufacturing contracts and capacity reservation arrangements to secure steady revenue streams and capacity utilization.